Optogenetics offers mutation-independent vision restoration for IRDs, with promising early-phase results in retinitis ...

AAVantgarde and AGC Biologics have entered into an agreement in which AGC Biologics will provide Good Manufacturing Practice manufacturing for AAVantgarde’s dual-vector gene therapies for inherited ...

Panelists discuss how key biologic and clinical distinctions—such as ischemia, leakage patterns, and modality-specific ...

The US Food and Drug Administration (FDA) has approved aflibercept injection 8 mg (EYLEA HD) from Regeneron Pharmaceuticals ...

Precise Bio has successfully treated a patient with PB-001, the company’s 3D-bio-printed corneal implant, at Rambam Medical ...

Foundation Fighting Blindness has granted public access to de-identified 4-year data from individuals participating in RUSH2A ...

AAO 2025 revealed that true-color widefield imaging, AI-powered home OCT, and refined FAERS analyses are collectively transforming retinal diagnostics into a more precise, continuous, and safety-aware ...

Coave Therapeutics has announced its lead gene therapy program, CoTx-101, for the treatment of retinal vascular diseases, ...

The trial is a phase 1/2 open-label, ascending-dose study of the safety and efficacy of OPGx-LCA5. Recently, the company ...

The discussion explores how basal and reflex tears differ and why composition impacts sustained eye comfort.

Apellis Pharmaceuticals recently announced post hoc analysis data of the GALE extension study. This new data is the result of ...

Panelists discuss how differing disease mechanisms, inflammatory drivers, and clinical priorities across AMD, DME, and RVO ...